References
- 1. Zakelj MP, Zadnik V, Zagar T, Zakotnik B. Survival of cancer patients, diagnosed in 1991-2005 in Slovenia. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2009. p. 229.
- 2. Treglia G, Taralli S, Salsano M, Muoio B, Sadeghi R, Giovanella L. Prevalence and malignancy risk of focal colorectal incidental uptake detected by 18F-FDG-PET or PET/CT: a meta-analysis. Radiol Oncol 2015; 49(2): 200-208.; 48: 99-104.
- 3. Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma. Radiol Oncol 2009; 43: 1-8.
- 4. Ocvirk J, Heeger S, McCloud P, Hofheinz RD. A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis. Radiol Oncol 2013; 47: 166-75.
- 5. Reeder CE, Gordon D. Managing oncology costs. Am J Manag Care., 2006; 12: 3-16.
- 6. Van Cutsem EJD, Oliveira J. On behalf of the ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19(Suppl 2): ii33-4.
- 7. Mesti T. [The cost of systemic therapy for metastatic colorectal carcinoma at Institute of Oncology Ljubljana in the year 2009]. Master’s thesis. [Slovenian]. University of Ljubljana, Faculty of Economics; 2011. Available at: http://www.cek.ef.uni-lj.si/magister/mesti4363.pdf
- 8. Song X, Zhao Z, Barber B, Gregory C, Zhun C, Sue G. Cost of illness in patients with metastatic colorectal cancer. J Med Econ 2011; 14: 1-9.
- 9. Ferro SA, Myer BS, Wolff DA, Poniewierski MS, Culakova E, Cosler LE, et al. Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care 2008; 14: 717-25.
- 10. Paramore LC, Thomas SK, Knopf KB. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer, 2006; 6: 52-8.
- 11. Bending WM, Trueman P, Lowson KV, Pilgrim H, Tappenden P, Chilcott J, et al. Estimating the direct costs of bowel cancer services provided by the National Health Service. Int J Technol Assess Health Care 2010; 26: 362-9.
- 12. Piškur P, Sonc M, Čufer T, Borštnar S, Mrhar A. Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: A Slovenian perspective. Anticancer Drugs, 2006; 17: 719-24.
- 13. Obradovič M, Mrhar A, Kos M. Cost effectiveness of UGT1A1 genotypes in second line, high dose, once every three week irinotecan monotherapy treatment of colorectal cancer. Pharmacogenomics 2008; 9: 539-49.
- 14. Organisation for Economic Cooperation and Development. Health data. 2008, May. Available from: http://www.oecd-ilibrary.org/economics/country-statistical-profile-slovenia_20752288-table-svn. Accessed 10 August 2011.
- 15. Marušič D, Ceglar J, Prevolnik-Rupel V. [Reimbursement of health care services with special attention paid to drg reimbursement system in Slovenia]. [Slovenian]. Zdrav Varst 2009; 48: 177-83.
- 16. Busse R. Moving from passive to active provider payment systems: DRGbased financing. International conference markets in European health systems: opportunities, challenges and limitations; 2009. Available from: http://www.cef-see.org/health/#. Accessed 20 May 2009.
- 17. Stariha J. [The adequacy of funding for acute hospital treatment after a system comparable groups of cases.] [Slovenian]. Master’s thesis. University of Primorska, Faculty of Management; 2009. Available at: http://www.ediplome.fm-kp.si/Stariha_Jurij_20091028.pdf. Accessed 10 August 2010.
- 18. Zupanc I. [DRG: questions and answers about the classification system and the financing of hospitals.][Slovenian].Ljubljana: Inštitut za varovanje zdravja RS; 2008.
- 19. Tekavčič M. [Cost management]. [Slovenian]. Ljubljana : Gospodarski vestnik, ISBN/ISSN: 867061149X; 1997.
- 20. Grandlich C. Using activity-based costing in surgery. AORN J, 2004; 79: 18-192.